查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1626520

注射筆市場：按產品、應用、最終用戶、筆配件、數量和地區劃分，2024 年至 2031 年

Injection Pen Market By Product, Application, End-Users, Pen Accessories, Dosage, & Region for 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

注射筆市場評估，2024-2031

由於糖尿病、類風濕性關節炎和多發性硬化症等慢性疾病的發生率不斷上升，注射筆市場正在大幅成長。這些疾病通常需要定期、精確地服用藥物，而這很難透過傳統的注射器來實現。注射筆使得這個過程變得非常簡單。注射筆的設計易於使用，使患者能夠以最小的不適和努力自行給藥。注射筆中預先裝有藥物，並具有可調節的劑量設置，使其更容易管理並減少劑量錯誤的機會。預計到 2024 年該市場的營收將超過 19 億美元，到 2031 年估值將達到約 25.8 億美元。

技術的進步使得注射筆更具吸引力。開發人員正在開發可以連接到行動應用程式的智慧筆，以提供患者提醒並追蹤藥物使用情況。這些特點有助於提高治療方案的依從性，這對於有效管理慢性疾病非常重要。此外，家庭醫療保健的興起和對微創治療的偏好日益增加，推動了注射筆的普及，預計 2024 年至 2031 年期間市場複合年增長率將達到 3.90%。

注射筆市場定義/概述

注射筆是一種透過針頭注射精確劑量藥物的醫療設備。它類似於一支巨型筆，旨在使患者註射藥物的過程更容易、更方便。注射筆通常用於注射糖尿病胰島素、生長激素以及治療類風濕性關節炎等自體免疫疾病。

注射筆的使用徹底改變了治療方案，提高了患者的依從性，同時減少了與傳統注射器注射相關的恐懼和不適。對於糖尿病患者來說，這些筆提供了一種管理血糖水平的簡單方法，使他們能夠過著更獨立的生活方式。準確分配劑量有助於確保藥物消耗的一致性，這對於保持健康和避免問題非常重要。此外，醫護人員也受益於該筆的便利，它簡化了給藥流程並減少了發生錯誤的可能性。

注射筆在醫療保健領域可能會變得越來越重要。一個值得注意的趨勢是易用性和自動化程度的日益提高。未來的注射筆可能具有更簡單的機制，以減少給藥所需的步驟，使更廣泛的患者能夠使用它們。此外，材料和技術的進步預計將提高準確性和可靠性，提供一致的劑量，並減少注射過程中的不適。

日益進步的技術會推動注射筆市場的發展嗎？

與小瓶和注射器等傳統的胰島素輸送方法相比，胰島素筆有幾個優點。目的是為了讓患者更輕鬆、更方便。與必須從小瓶注射的注射器不同，胰島素筆預先裝有胰島素筒。這使得它易於使用，特別是對於每天需要注射幾次胰島素的患者。它體積不大，設計精巧且易於攜帶，讓您在各種社交場合更輕鬆地進行糖尿病管理。胰島素筆的一大優點就是使用方便。許多現代版本都力求方便用戶，幾乎不需要任何指導。

自動注射器和以推注幫浦為基礎的系統等注射裝置的發展體現了這種奉獻精神。這些設備旨在提供一種輸送藥物（包括胰島素）的替代方法，並且正在評估其安全有效地分配藥物同時提高患者依從性的能力。

胰島素筆、自動注射器和基於推注幫浦的系統等注射設備的出現代表了醫療保健技術的重大進步。這些改進不僅使患者能夠更輕鬆、更舒適地管理他們的慢性疾病，而且還有助於提高他們對治療方案的依從性。隨著科技的進步，我們可以期待未來越來越複雜和個人化的解決方案，以滿足世界各地患者的多樣化需求。

替代藥物輸送會阻礙注射筆市場嗎？

替代形式的藥物輸送可能會對注射筆業務產生影響，但這取決於許多情況。替代技術包括口服藥片、貼片、吸入器以及植入式設備和微針等新技術。每種方法都有其獨特的優勢，如方便、減輕疼痛和延長藥物釋放時間，可能會吸引那些覺得注射困難或不方便的患者。例如，口服藥物因其簡單和非侵入性而廣受歡迎。許多人選擇服用藥丸而不是使用注射筆。這種輸送方法對於經由消化道完整吸收的藥物特別有用。同樣，透皮貼片可以透過皮膚持續釋放藥物，確保血中濃度穩定，並消除藥物的副作用。

儘管其他形式的藥物傳遞提供了可行的解決方案，每種方式都有各自的優點，但注射筆由於其公認的有效性、簡單性和持續的技術發展而仍然受歡迎。特定藥物、患者偏好和病情類型通常決定是否使用注射筆或其他技術。隨著醫療保健的發展，注射筆產業可能會適應、創新並在患者可用的各種藥物輸送方法中佔據一席之地。

目錄

第 1 章簡介

  • 市場定義
  • 市場區隔
  • 調查安排
  • 先決條件
  • 限制

第 2 章 研究方法

  • 資料探勘
  • 二次研究
  • 初步研究
  • 專家建議
  • 品質檢查
  • 最終審核
  • 數據三角測量
  • 由下而上的方法
  • 自上而下的方法
  • 調查流程
  • 資料來源

第 3 章執行摘要

  • 全球注射筆市場概覽
  • 2021 年至 2030 年全球注射筆估計與預測
  • 全球注射筆的生態地圖
  • 競爭力分析：漏斗圖
  • 全球注射筆市場的絕對收入機會
  • 全球注射筆市場吸引力分析（按地區）
  • 全球注射筆市場吸引力分析（按產品）
  • 全球注射筆市場吸引力分析（按應用）
  • 按劑量進行全球注射筆市場吸引力分析
  • 全球注射筆市場吸引力分析（按最終用戶）
  • 全球注射筆市場吸引力分析（按筆配件）
  • 全球注射筆市場區域分析
  • 全球注射筆市場（依產品劃分）
  • 全球注射筆市場（按應用）
  • 全球注射筆市場（按劑量）
  • 全球注射筆市場（以最終用戶劃分）
  • 全球注射筆市場（以筆配件劃分）
  • 全球注射筆市場（按地區）
  • 未來市場機會

第四章 市場展望

  • 全球注射筆市場的變化
  • 注射筆市場前景
  • 市場推動因素
    • 慢性病發生率上升
    • 老年人口增加
  • 市場限制
    • 注射筆成本高
    • 針刺傷與誤用
  • 市場趨勢
    • 技術進步
    • 自行服藥越來越普遍
  • 市場機會
    • 使用可生物降解的筆材料
    • 進入新興市場
  • 波特五力分析
    • 新進入者的威脅
    • 替代品的威脅
    • 供應商的議價能力
    • 買家的議價能力
    • 競爭對手之間的競爭
  • 宏觀經濟分析
  • 價值鏈分析
  • 價格分析
  • 注射筆配件案例分析
  • 世界肥胖展望
  • 將 GLP-1RA 納入註射器及其對糖尿病和肥胖的影響
  • 生長激素缺乏症及其市場趨勢
  • 注射筆排行榜

第 5 章：產品市場

  • 概述
  • 全球注射筆市場：按產品劃分的基點佔有率 (BPS) 分析
  • 一次性
  • 可重複使用

第六章：依劑量劃分的市場

  • 概述
  • 全球注射筆市場：劑量、基點佔有率 (BPS) 分析
  • 已修復
  • 變數

第 7 章 依應用劃分的市場

  • 概述
  • 全球注射筆市場：按應用劃分的基點佔有率 (BPS) 分析
  • 糖尿病
  • 過敏反應
  • 骨質疏鬆症
  • 生長激素缺乏
  • 關節炎
  • 其他

第 8 章 最終用戶市場

  • 概述
  • 全球注射筆市場：按最終用戶劃分的基點佔有率 (BPS) 分析
  • 醫院和診斷中心
  • 居家護理

第 9 章：筆配件市場

  • 概述
  • 筆尖
  • 針套或護罩
  • 便攜包
  • 筆柄或筆架

第 10 章 區域市場

  • 概述
  • 北美洲
    • 北美市場概況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲市場概況
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
    亞太地區
      亞太市場概況
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 拉丁美洲市場概況
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 中東和非洲
    • 中東和非洲市場概況
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

第 11 章 競爭格局

  • 概述
  • 重大進展
  • 公司市場排名分析
  • 地理足跡 ACE矩陣
    • Active
    • Cutting Edge
    • Emerging
    • Innovator

第 12 章全球注射筆市場、公司簡介

  • ELI LILLY AND COMPANY
  • SANOFI SA
  • NOVO NORDISK A/S
  • MERCK KGAA
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • OWEN MUMFORD
  • HASELMEIER GMBH
  • GERRESHEIMER AG
  • BIOCON LIMITED
  • BD (BECKTON DISCKINSON CO)
  • ASTRAZENECA
  • SHL MEDICAL
  • NOVARTIS AG
  • SOLTEAM INCORPORATION CO., LTD.
  • YPSOMED AG
  • ROCHE HOLDING AG
  • NORDIC PHARMA
  • PHILLIPS-MEDISIZE CORPORATION (A MOLEX COMPANY)
  • MEDTRONIC

第 13 章 全球注射筆配件市場、公司簡介

  • 糖尿病快訊
  • 糖尿病倉庫
  • 4ALLFAMILY
Product Code: 26272

Injection Pen Market Valuation - 2024-2031

The injection pen market is expanding significantly due to the increasing prevalence of chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis. These illnesses frequently necessitate regular, exact amounts of medication which can be challenging to administer with conventional syringes. Injection pens make the process considerably easier. They are intended to be user-friendly allowing patients to self-administer medication with minimal discomfort and effort. The pens come pre-filled with medication and feature changeable dose settings making them easy and lowering the chance of dosing errors by enabling the market to surpass a revenue of USD 1.90 Billion valued in 2024 and reach a valuation of around USD 2.58 Billion by 2031.

Advancements in technology are making injection pens even more appealing. Manufacturers are developing smart pens that can connect to mobile apps providing patients with reminders and tracking their medication usage. These features help improve adherence to treatment regimens which is crucial for managing chronic diseases effectively. Additionally, the growing trend towards home healthcare and the increasing preference for minimally invasive treatments are boosting the adoption of injection pens by enabling the market to grow at a CAGR of 3.90% from 2024 to 2031.

Injection Pen Market: Definition/ Overview

Injection pen is a medical gadget used to provide precise amounts of medication via a needle. It resembles a huge pen and is intended to make the procedure of injecting drugs simpler and more convenient for patients. Injection pens are frequently used to provide medications such as insulin for diabetes, growth hormones, and some treatments for autoimmune disorders such as rheumatoid arthritis.

The use of injectable pens has transformed treatment regimens by increasing patient compliance while decreasing the fear and discomfort associated with traditional syringe injections. For diabetic patients, these pens provide a simple way to manage blood sugar levels enabling a more independent lifestyle. Precision in dose distribution contributes to drug consumption consistency which is critical for preserving health and avoiding issues. Furthermore, healthcare personnel benefit from the pens simplicity which streamlines the administration process and reduces the possibility of errors.

Injection pens are likely to become increasingly important in healthcare. One notable trend is their ongoing development in usability and automation. Future injectable pens may have even simpler mechanisms lowering the number of steps necessary for administration and making them available to a broader spectrum of patients. Furthermore, advances in materials and technology are projected to improve their precision and dependability providing constant dosage distribution and reducing discomfort during injection procedures.

Will the Increasing Technological Advancements Drive the Injection Pen Market?

Insulin pens offer various advantages over traditional methods of insulin delivery such as vials and syringes. They are intended to be easier and more convenient for patients. Unlike syringes which must be drawn from a vial and then injected, insulin pens are pre-filled with insulin cartridges. This makes them easier to use particularly for patients who require insulin several times per day. Users find them more rewarding because they are less bulky, inconspicuous, and portable making diabetes management easier in a variety of social situations. One major advantage of insulin pens is their ease of usage. Many contemporary versions are meant to be user-friendly requiring little instruction.

The development of injection devices such as autoinjectors and bolus pump-based systems demonstrates this dedication. These devices are intended to provide alternate methods of delivering pharmaceuticals including insulin, and are evaluated on their capacity to dispense drugs safely and effectively while increasing patient compliance.

The emergence of injection devices like as insulin pens, autoinjectors, and bolus pump-based systems represents a huge step forward in healthcare technology. These improvements not only make it easier and more comfortable for patients to manage chronic illnesses but they also help to enhance treatment regimen adherence. As technology advances, the future promises increasingly more complex and individualized solutions to satisfy the different requirements of patients around the world.

Will Alternative Modes of Drug Delivery Hamper the Injection Pen Market?

Alternative forms of medication delivery may have an impact on the injectable pen business but this relies on a number of circumstances. Alternative techniques include oral pills, patches, inhalers, and more recent technology such as implanted devices or microneedles. Each of these methods provides distinct benefits such as convenience, reduced pain, or extended medication release which may appeal to patients who find injections difficult or inconvenient. Oral drugs, for example, are popular due to their simplicity and non-invasiveness. Many people choose to ingest pills rather than use injectable pens. This method of distribution is especially useful for pharmaceuticals that can be absorbed via the digestive system without degradation. Similarly, transdermal patches allow continuous medication release through the skin, ensuring stable blood levels and eliminating

Alternative forms of medication delivery offer viable solutions with their own set of benefits but injectable pens remain popular because to their proven effectiveness, ease, and continual technical developments. The precise drug, patient preferences, and type of the medical condition are frequently used to determine whether to use injectable pens or other techniques. As healthcare evolves, the injectable pen industry is likely to adapt and innovate ensuring its place among the variety of medication delivery methods available to patients.

Category-Wise Acumens

How Convenience and Ease of Use Drive the Product Segment?

Disposable injection pens is projected to hold major share in the market. This domination stems mostly from the convenience and ease of usage provided by disposable pens. Patients prefer them since they do not require maintenance, cleaning, or the trouble of changing cartridges. These pens are simply thrown after use which is especially useful for people who may struggle to keep a reusable pen in good condition or who want a simple, one-time-use option. This simplicity and user-friendliness increase their popularity among patients resulting in increased adoption rates.

Disposable injectable pens are popular in the healthcare business because they minimize the danger of contamination and infection. Because each pen is only used once, there is less risk of poor cleaning or reuse which can lead to hygiene problems. This makes disposable pens a safer option particularly for frequently injected drugs such as insulin for diabetes. Furthermore, the pharmaceutical industry's emphasis on patient safety and adherence has resulted in the creation of more complex disposable pens including dose memory, automatic needle retraction, and ergonomic designs. These advancements improve the user experience making disposable pens the preferable option. The combination of convenience, safety, and constant innovation has secured the leading position of disposable injection pens in the market.

How do Increasing Awareness and Diagnosis of Diabetes Drive the Application Segment?

The diabetic category dominates the injectable pen market. This dominance stems primarily from the high prevalence of diabetes globally and the need for regular insulin therapy among diabetic individuals. Insulin pens provide diabetics a convenient, accurate, and user-friendly way to manage their condition. Unlike traditional syringes, insulin pens are simple to use, portable, and engineered to provide exact insulin dosages which are critical for keeping blood sugar levels within a specific range. Diabetes therapy necessitates frequently daily injections, therefore demand for insulin pens stays constantly high contributing to the segment's market domination.

As diabetes knowledge and diagnosis have increased so has the number of patients who require insulin therapy. This has fueled innovation and advancements in injectable pen technology making them more accessible and effective for patients. Companies are constantly creating pens with advanced features including digital displays, memory functions, and dose adjusting mechanisms to improve user experience and adherence to therapy. These improvements together with the chronic nature of diabetes and insulin's critical role in its care ensure that the diabetes application category remains the largest and most influential in the injection pen market.

Gain Access into Injection Pen Market Report Methodology

Country/Region-wise Acumens

How Advancement's in Drug Delivery Technology Drive the Market in North America?

North America is expected to hold major share in the market for injectable pens owing to the rising prevalence of chronic diseases and higher healthcare expenditures in the region. Several important reasons are driving the injection pen market including the rising prevalence of chronic diseases and the growing need for user-friendly medication delivery systems.

According to the International Diabetes Federation, the number of individuals with diabetes is anticipated to increase from 537 million in 2021 to 783 million by 2045. This tendency is especially noteworthy in regions like North America where diabetes is common. For example, the US Centers for Disease Control and Prevention (CDC) estimated that approximately 34.2 million people in the United States had diabetes in 2020.

According to the Centers for Disease Control and Prevention, around 34.2 million individuals in the United States have diabetes in 2020 with another 88 million having pre-diabetes. The growing awareness of new drug delivery devices, the widespread availability of injection pens and cartridges, and the emphasis on patient-centered treatment have all contributed to the rise of the North American injection pen industry.

How Growing Awareness about Advanced Medication Delivery Devices Drive the Market in Asia Pacific Region?

Asia Pacific is expected to be the fastest-growing region in the injection pen market owing to the rising incidence of chronic diseases. Also, the rising healthcare spending is upsurging awareness of improved medicine delivery systems, thereby enhancing the sales of injection pen. The rising prevalence of chronic diseases such as cancer, cardiovascular disease, and autoimmune disorders among the Asian Pacific population owing to poor eating habits, physical inactivity, and increasing alcohol consumption is expected to drive demand for injection pens in the region. Furthermore, pharmaceutical makers increasing investments in the research of new pharmaceuticals as well as the increased emphasis on patient-centered care are helping to drive growth in the Asia Pacific injection pen market.

Technological developments in injection pen design such as the incorporation of smart features and increased dosing precision have also contributed significantly to market expansion. These innovations have improved patient adherence and safety making injectable pens more desirable to both physicians and patients. Furthermore, rising healthcare costs and greater awareness of improved pharmaceutical administration methods have accelerated the global usage of injection pens.

Competitive Landscape

The injection pen market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the injection pen market include:

Novo Nordisk A/S

Medtronic plc

Becton, Dickinson and Company

Sanofi

Eli Lilly and Company

Merck

AstraZeneca

Hoffmann-La Roche Ltd.

Owen Mumford Ltd

Ypsomed AG

Terumo Medical Corporation

Braun Medical

Sun Pharmaceutical Industries Ltd.

Latest Developments

In April 2021, Roche Diabetes Care France and BioCorp will debut the Mallya smart insulin pen device in France.

In March 2022, Novo Nordisk announced its first smart insulin pens. The NovoPen Echo Plus and NovoPen 6 are insulin self-injection pens that gather data, such as how much and when insulin is administered, and then upload it to an app via a near-field communication (NFC) link for healthcare professionals and patients to review.

Injection Pen Market, By Category

  • Product:
  • Disposable
  • Reusable
  • Application:
  • Diabetes
  • Anaphylaxis
  • Osteoporosis
  • Growth Hormone Deficiency
  • Arthritis
  • Others
  • End-Users:
  • Hospitals & Diagnostic Centers
  • Homecare
  • Pen Accessories:
  • Pen Needle Tips
  • Needle Covers or Shields
  • Carry Cases
  • Pen Grips or Holders
  • Others
  • Dosage:
  • Variable
  • Fixed
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL INJECTION PEN MARKET OVERVIEW
  • 3.2 GLOBAL INJECTION PEN ESTIMATES AND FORECAST (USD MILLION), 2021-2030
  • 3.3 GLOBAL INJECTION PEN ECOLOGY MAPPING
  • 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • 3.5 GLOBAL INJECTION PEN ABSOLUTE MARKET OPPORTUNITY
  • 3.6 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • 3.7 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT
  • 3.8 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
  • 3.9 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY DOSAGE
  • 3.10 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY END-USERS
  • 3.11 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY PEN ACCESSORIES
  • 3.12 GLOBAL INJECTION PEN MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.13 GLOBAL INJECTION PEN MARKET, BY PRODUCT (USD MILLION)
  • 3.14 GLOBAL INJECTION PEN MARKET, BY APPLICATION (USD MILLION)
  • 3.15 GLOBAL INJECTION PEN MARKET, BY DOSAGE (USD MILLION)
  • 3.16 GLOBAL INJECTION PEN MARKET, BY END-USERS (USD MILLION)
  • 3.17 GLOBAL INJECTION PEN MARKET, BY PEN ACCESSORIES (USD MILLION)
  • 3.18 GLOBAL INJECTION PEN MARKET, BY GEOGRAPHY (USD MILLION)
  • 3.19 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

  • 4.1 GLOBAL INJECTION PEN MARKET EVOLUTION
  • 4.2 INJECTION PEN MARKET OUTLOOK
  • 4.3 MARKET DRIVERS
    • 4.3.1 RISING PREVALENCE OF CHRONIC DISEASES
    • 4.3.2 INCREASING GERIATRIC POPULATION
  • 4.4 MARKET RESTRAINTS
    • 4.4.1 HIGH COST OF INJECTION PENS
    • 4.4.2 NEEDLE-STICK INJURIES AND MISUSE
  • 4.5 MARKET TRENDS
    • 4.5.1 TECHNOLOGICAL ADVANCEMENTS
    • 4.5.2 RISING POPULARITY OF SELF-ADMINISTRATION OF DRUGS
  • 4.6 MARKET OPPORTUNITY
    • 4.6.1 CAPITALIZING ON BIODEGRADABLE PEN MATERIALS
    • 4.6.2 EXPANSION INTO EMERGING MARKET
  • 4.7 PORTER'S FIVE FORCES ANALYSIS
    • 4.7.1 THREAT OF NEW ENTRANTS
    • 4.7.2 THREAT OF SUBSTITUTES
    • 4.7.3 BARGAINING POWER OF SUPPLIERS
    • 4.7.4 BARGAINING POWER OF BUYERS
    • 4.7.5 COMPETITIVE RIVALRY
  • 4.8 MACROECONOMIC ANALYSIS
  • 4.9 VALUE CHAIN ANALYSIS
  • 4.10 PRICING ANALYSIS
  • 4.11 ANALYSIS ON ACCESSORY CASES FOR INJECTION PENS
  • 4.12 GLOBAL OBESITY OUTLOOK
  • 4.13 GLP-1RA ADOPTION IN INJECTION PENS AND ITS IMPACT ON DIABETICS AND OBESITY
  • 4.14 GROWTH HARMONE DEFICIENCY AND ITS MARKET TRENDS
  • 4.15 LIST OF TOP INJECTION PENS

5 MARKET, BY PRODUCT

  • 5.1 OVERVIEW
  • 5.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT
  • 5.3 DISPOSABLE
  • 5.4 REUSABLE

6 MARKET, BY DOSAGE

  • 6.1 OVERVIEW
  • 6.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY DOSAGE
  • 6.3 FIXED
  • 6.4 VARIABLE

7 MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
  • 7.3 DIABETES
  • 7.4 ANAPHYLAXIS
  • 7.5 OSTEOPOROSIS
  • 7.6 GROWTH HORMONE DEFICIENCY
  • 7.7 ARTHRITIS
  • 7.8 OTHERS

8 MARKET, BY END USERS

  • 8.1 OVERVIEW
  • 8.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END USERS
  • 8.3 HOSPITALS & DIAGNOSTIC CENTERS
  • 8.4 HOMECARE

9 MARKET, BY PEN ACCESSORIES

  • 9.1 OVERVIEW
  • 9.2 PEN NEEDLE TIPS
  • 9.3 NEEDLE COVERS OR SHIELDS
  • 9.4 CARRY CASES
  • 9.5 PEN GRIPS OR HOLDERS

10 MARKET, BY GEOGRAPHY

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA MARKET SNAPSHOT
    • 10.2.2 U.S.
    • 10.2.3 CANADA
    • 10.2.4 MEXICO
  • 10.3 EUROPE
    • 10.3.1 EUROPE MARKET SNAPSHOT
    • 10.3.2 GERMANY
    • 10.3.3 U.K.
    • 10.3.4 FRANCE
    • 10.3.5 ITALY
    • 10.3.6 SPAIN
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC MARKET SNAPSHOT
    • 10.4.2 CHINA
    • 10.4.3 JAPAN
    • 10.4.4 INDIA
    • 10.4.5 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 LATIN AMERICA MARKET SNAPSHOT
    • 10.5.2 BRAZIL
    • 10.5.3 ARGENTINA
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST AND AFRICA
    • 10.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
    • 10.6.2 UAE
    • 10.6.3 SAUDI ARABIA
    • 10.6.4 SOUTH AFRICA
    • 10.6.5 REST OF MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY DEVELOPMENT
  • 11.3 COMPANY MARKET RANKING ANALYSIS
  • 11.4 COMPANY REGIONAL FOOTPRINT
  • 11.5 ACE MATRIX
    • 11.5.1 ACTIVE
    • 11.5.2 CUTTING EDGE
    • 11.5.3 EMERGING
    • 11.5.4 INNOVATORS

12 GLOBAL INJECTION PEN MARKET COMPANY PROFILES

  • 12.1 ELI LILLY AND COMPANY
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 COMPANY INSIGHTS
    • 12.1.3 PRODUCT BENCHMARKING
    • 12.1.4 KEY DEVELOPMENTS
    • 12.1.5 WINNING IMPERATIVES
    • 12.1.6 CURRENT FOCUS & STRATEGIES
    • 12.1.7 SWOT ANALYSIS
    • 12.1.8 THREAT FROM COMPETITION
  • 12.2 SANOFI SA
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 COMPANY INSIGHTS
    • 12.2.3 PRODUCT BENCHMARKING
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
    • 12.2.6 WINNING IMPERATIVES
    • 12.2.7 CURRENT FOCUS & STRATEGIES
    • 12.2.8 THREAT FROM COMPETITION
  • 12.3 NOVO NORDISK A/S
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 COMPANY INSIGHTS
    • 12.3.3 PRODUCT BENCHMARKING
    • 12.3.4 KEY DEVELOPMENTS
    • 12.3.5 WINNING IMPERATIVES
    • 12.3.6 CURRENT FOCUS & STRATEGIES
    • 12.3.7 SWOT ANALYSIS
    • 12.3.8 THREAT FROM COMPETITION
  • 12.4 MERCK KGAA
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 COMPANY INSIGHTS
    • 12.4.3 PRODUCT BENCHMARKING
    • 12.4.4 KEY DEVELOPMENTS
    • 12.4.5 WINNING IMPERATIVES
    • 12.4.6 CURRENT FOCUS & STRATEGIES
    • 12.4.7 THREAT FROM COMPETITION
  • 12.5 TEVA PHARMACEUTICALS INDUSTRIES LTD.
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 COMPANY INSIGHTS
    • 12.5.3 PRODUCT BENCHMARKING
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 WINNING IMPERATIVES
    • 12.5.6 CURRENT FOCUS & STRATEGIES
    • 12.5.7 THREAT FROM COMPETITION
  • 12.6 OWEN MUMFORD
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 COMPANY INSIGHTS
    • 12.6.3 PRODUCT BENCHMARKING
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 WINNING IMPERATIVES
    • 12.6.6 CURRENT FOCUS & STRATEGIES
    • 12.6.7 THREAT FROM COMPETITION
  • 12.7 HASELMEIER GMBH
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 COMPANY INSIGHTS
    • 12.7.3 PRODUCT BENCHMARKING
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 WINNING IMPERATIVES
    • 12.7.6 CURRENT FOCUS & STRATEGIES
    • 12.7.7 THREAT FROM COMPETITION
  • 12.8 GERRESHEIMER AG
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 COMPANY INSIGHTS
    • 12.8.3 PRODUCT BENCHMARKING
    • 12.8.4 WINNING IMPERATIVES
    • 12.8.5 CURRENT FOCUS & STRATEGIES
    • 12.8.6 THREAT FROM COMPETITION
  • 12.9 BIOCON LIMITED
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 COMPANY INSIGHTS
    • 12.9.3 PRODUCT BENCHMARKING
    • 12.9.4 WINNING IMPERATIVES
    • 12.9.5 CURRENT FOCUS & STRATEGIES
    • 12.9.6 THREAT FROM COMPETITION
  • 12.10 BD (BECKTON DISCKINSON CO)
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 COMPANY INSIGHTS
    • 12.10.3 PRODUCT BENCHMARKING
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 WINNING IMPERATIVES
    • 12.10.6 CURRENT FOCUS & STRATEGIES
    • 12.10.7 THREAT FROM COMPETITION
  • 12.11 ASTRAZENECA
    • 12.11.1 COMPANY OVERVIEW
    • 12.11.2 COMPANY INSIGHTS
    • 12.11.3 PRODUCT BENCHMARKING
    • 12.11.4 WINNING IMPERATIVES
    • 12.11.5 CURRENT FOCUS & STRATEGIES
    • 12.11.6 THREAT FROM COMPETITION
  • 12.12 SHL MEDICAL
    • 12.12.1 COMPANY OVERVIEW
    • 12.12.2 COMPANY INSIGHTS
    • 12.12.3 PRODUCT BENCHMARKING
    • 12.12.4 KEY DEVELOPMENTS
    • 12.12.5 WINNING IMPERATIVES
    • 12.12.6 CURRENT FOCUS & STRATEGIES
    • 12.12.7 THREAT FROM COMPETITION
  • 12.13 NOVARTIS AG
    • 12.13.1 COMPANY OVERVIEW
    • 12.13.2 COMPANY INSIGHTS
    • 12.13.3 PRODUCT BENCHMARKING
    • 12.13.4 KEY DEVELOPMENTS
    • 12.13.5 WINNING IMPERATIVES
    • 12.13.6 CURRENT FOCUS & STRATEGIES
    • 12.13.7 THREAT FROM COMPETITION
  • 12.14 SOLTEAM INCORPORATION CO., LTD.
    • 12.14.1 COMPANY OVERVIEW
    • 12.14.2 COMPANY INSIGHTS
    • 12.14.3 PRODUCT BENCHMARKING
    • 12.14.4 KEY DEVELOPMENTS
    • 12.14.5 WINNING IMPERATIVES
    • 12.14.6 CURRENT FOCUS & STRATEGIES
    • 12.14.7 THREAT FROM COMPETITION
  • 12.15 YPSOMED AG
    • 12.15.1 COMPANY OVERVIEW
    • 12.15.2 COMPANY INSIGHTS
    • 12.15.3 PRODUCT BENCHMARKING
    • 12.15.4 KEY DEVELOPMENTS
    • 12.15.5 WINNING IMPERATIVES
    • 12.15.6 CURRENT FOCUS & STRATEGIES
    • 12.15.7 THREAT FROM COMPETITION
  • 12.16 ROCHE HOLDING AG
    • 12.16.1 COMPANY OVERVIEW
    • 12.16.2 COMPANY INSIGHTS
    • 12.16.3 PRODUCT BENCHMARKING
    • 12.16.4 KEY DEVELOPMENTS
    • 12.16.5 WINNING IMPERATIVES
    • 12.16.6 CURRENT FOCUS & STRATEGIES
    • 12.16.7 THREAT FROM COMPETITION
  • 12.17 NORDIC PHARMA
    • 12.17.1 COMPANY OVERVIEW
    • 12.17.2 COMPANY INSIGHTS
    • 12.17.3 PRODUCT BENCHMARKING
    • 12.17.4 KEY DEVELOPMENTS
    • 12.17.5 WINNING IMPERATIVES
    • 12.17.6 CURRENT FOCUS & STRATEGIES
    • 12.17.7 THREAT FROM COMPETITION
  • 12.18 PHILLIPS-MEDISIZE CORPORATION (A MOLEX COMPANY)
    • 12.18.1 COMPANY OVERVIEW
    • 12.18.2 COMPANY INSIGHTS
    • 12.18.3 PRODUCT BENCHMARKING
    • 12.18.4 KEY DEVELOPMENTS
    • 12.18.5 WINNING IMPERATIVES
    • 12.18.6 CURRENT FOCUS & STRATEGIES
    • 12.18.7 THREAT FROM COMPETITION
  • 12.19 MEDTRONIC
    • 12.19.1 COMPANY OVERVIEW
    • 12.19.2 COMPANY INSIGHTS
    • 12.19.3 PRODUCT BENCHMARKING
    • 12.19.4 KEY DEVELOPMENTS
    • 12.19.5 WINNING IMPERATIVES
    • 12.19.6 CURRENT FOCUS & STRATEGIES
    • 12.19.7 THREAT FROM COMPETITION

13 GLOBAL INJECTION PEN ACCESSORIES MARKET COMPANY PROFILES

  • 13.1 DIABETES EXPRESS
    • 13.1.1 COMPANY OVERVIEW
    • 13.1.2 COMPANY INSIGHTS
    • 13.1.3 PRODUCT BENCHMARKING
  • 13.2 DIABETICWAREHOUSE
    • 13.2.1 COMPANY OVERVIEW
    • 13.2.2 COMPANY INSIGHTS
    • 13.2.3 PRODUCT BENCHMARKING
  • 13.3 4ALLFAMILY
    • 13.3.1 COMPANY OVERVIEW
    • 13.3.2 COMPANY INSIGHTS
    • 13.3.3 PRODUCT BENCHMARKING

LIST OF TABLES

  • TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 3 GLOBAL INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 4 GLOBAL INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 5 GLOBAL INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 6 GLOBAL INJECTION PEN MARKET, BY PEN ACCESSORIES, 2021-2030 (USD MILLION)
  • TABLE 7 GLOBAL INJECTION PEN MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
  • TABLE 8 NORTH AMERICA INJECTION PEN MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
  • TABLE 9 NORTH AMERICA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 10 NORTH AMERICA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 11 NORTH AMERICA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 12 NORTH AMERICA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 13 NORTH AMERICA INJECTION PEN MARKET, BY PEN ACCESSORIES, 2021-2030 (USD MILLION)
  • TABLE 14 U.S. INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 15 U.S. INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 16 U.S. INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 17 U.S. INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 18 CANADA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 19 CANADA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 20 CANADA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 21 CANADA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 22 MEXICO INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 23 MEXICO INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 24 MEXICO INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 25 MEXICO INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 26 EUROPE INJECTION PEN MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
  • TABLE 27 EUROPE INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 28 EUROPE INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 29 EUROPE INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 30 EUROPE INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 31 EUROPE INJECTION PEN MARKET, BY PEN ACCESSORIES, 2021-2030 (USD MILLION)
  • TABLE 32 GERMANY INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 33 GERMANY INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 34 GERMANY INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 35 GERMANY INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 36 U.K. INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 37 U.K. INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 38 U.K. INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 39 U.K. INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 40 FRANCE INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 41 FRANCE INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 42 FRANCE INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 43 FRANCE INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 44 ITALY INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 45 ITALY INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 46 ITALY INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 47 ITALY INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 48 SPAIN INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 49 SPAIN INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 50 SPAIN INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 51 SPAIN INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 52 REST OF EUROPE INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 53 REST OF EUROPE INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 54 REST OF EUROPE INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 55 REST OF EUROPE INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 56 ASIA PACIFIC INJECTION PEN MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
  • TABLE 57 ASIA PACIFIC INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 58 ASIA PACIFIC INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 59 ASIA PACIFIC INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 60 ASIA PACIFIC INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 61 ASIA PACIFIC INJECTION PEN MARKET, BY PEN ACCESSORIES, 2021-2030 (USD MILLION)
  • TABLE 62 CHINA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 63 CHINA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 64 CHINA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 65 CHINA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 66 JAPAN INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 67 JAPAN INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 68 JAPAN INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 69 JAPAN INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 70 INDIA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 71 INDIA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 72 INDIA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 73 INDIA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 74 REST OF ASIA PACIFIC INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 75 REST OF ASIA PACIFIC INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 76 REST OF ASIA PACIFIC INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 77 REST OF ASIA PACIFIC INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 78 LATIN AMERICA INJECTION PEN MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
  • TABLE 79 LATIN AMERICA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 80 LATIN AMERICA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 81 LATIN AMERICA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 82 LATIN AMERICA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 83 LATIN AMERICA INJECTION PEN MARKET, BY PEN ACCESSORIES, 2021-2030 (USD MILLION)
  • TABLE 84 BRAZIL INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 85 BRAZIL INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 86 BRAZIL INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 87 BRAZIL INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 88 ARGENTINA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 89 ARGENTINA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 90 ARGENTINA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 91 ARGENTINA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 92 REST OF LATIN AMERICA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 93 REST OF LATIN AMERICA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 94 REST OF LATIN AMERICA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 95 REST OF LATIN AMERICA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 96 MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
  • TABLE 97 MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 98 MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 99 MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 100 MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 101 MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY PEN ACCESSORIES, 2021-2030 (USD MILLION)
  • TABLE 102 UAE INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 103 UAE INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 104 UAE INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 105 UAE INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 106 SAUDI ARABIA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 107 SAUDI ARABIA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 108 SAUDI ARABIA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 109 SAUDI ARABIA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 110 SOUTH AFRICA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 111 SOUTH AFRICA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 112 SOUTH AFRICA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 113 SOUTH AFRICA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 114 REST OF MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
  • TABLE 115 REST OF MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY DOSAGE, 2021-2030 (USD MILLION)
  • TABLE 116 REST OF MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
  • TABLE 117 REST OF MIDDLE EAST AND AFRICA INJECTION PEN MARKET, BY END USERS, 2021-2030 (USD MILLION)
  • TABLE 118 COMPANY MARKET RANKING ANALYSIS
  • TABLE 119 COMPANY REGIONAL FOOTPRINT
  • TABLE 120 ELI LILLY: PRODUCT BENCHMARKING
  • TABLE 121 ELI LILLY: KEY DEVELOPMENTS
  • TABLE 122 ELI LILLY: WINNING IMPERATIVES
  • TABLE 123 SANOFI SA: PRODUCT BENCHMARKING
  • TABLE 124 SANOFI SA: KEY DEVELOPMENTS
  • TABLE 125 SANOFI SA: WINNING IMPERATIVES
  • TABLE 126 NOVO NORDISK A/S: PRODUCT BENCHMARKING
  • TABLE 127 NOVO NORDISK A/S: KEY DEVELOPMENTS
  • TABLE 128 NOVO NORDISK A/S: WINNING IMPERATIVES
  • TABLE 129 MERCK KGAA: PRODUCT BENCHMARKING
  • TABLE 130 MERCK KGAA: KEY DEVELOPMENTS
  • TABLE 131 MERCK KGAA: WINNING IMPERATIVES
  • TABLE 132 TEVA PHARMACEUTICALS: PRODUCT BENCHMARKING
  • TABLE 133 TEVA PHARMACEUTICALS: KEY DEVELOPMENTS
  • TABLE 134 TEVA PHARMACEUTICALS INDUSTRIES LTD.: WINNING IMPERATIVES
  • TABLE 135 OWEN MUMFORD: PRODUCT BENCHMARKING
  • TABLE 136 OWEN MUMFORD: KEY DEVELOPMENTS
  • TABLE 137 OWEN MUMFORD: WINNING IMPERATIVES
  • TABLE 138 HASELMEIER GMBH: PRODUCT BENCHMARKING
  • TABLE 139 HASELMEIER GMBH: KEY DEVELOPMENTS
  • TABLE 140 HASELMEIER GMBH: WINNING IMPERATIVES
  • TABLE 141 GERRESHEIMER AG: PRODUCT BENCHMARKING
  • TABLE 142 GERRESHEIMER AG: WINNING IMPERATIVES
  • TABLE 143 BIOCON LIMITED: PRODUCT BENCHMARKING
  • TABLE 144 BIOCON LIMITED: WINNING IMPERATIVES
  • TABLE 145 BD: PRODUCT BENCHMARKING
  • TABLE 146 BD: KEY DEVELOPMENTS
  • TABLE 147 BD (BECKTON DISCKINSON CO): WINNING IMPERATIVES
  • TABLE 148 ASTRAZENECA: PRODUCT BENCHMARKING
  • TABLE 149 ASTRAZENECA: WINNING IMPERATIVES
  • TABLE 150 SHL MEDICAL: PRODUCT BENCHMARKING
  • TABLE 151 SHL MEDICAL: KEY DEVELOPMENTS
  • TABLE 152 SHL MEDICAL: WINNING IMPERATIVES
  • TABLE 153 NOVARTIS AG: PRODUCT BENCHMARKING
  • TABLE 154 NOVARTIS AG: KEY DEVELOPMENTS
  • TABLE 155 NOVARTIS AG: WINNING IMPERATIVES
  • TABLE 156 SOLTEAM INCORPORATION CO., LTD.: PRODUCT BENCHMARKING
  • TABLE 157 SOLTEAM INCORPORATION CO., LTD.: KEY DEVELOPMENTS
  • TABLE 158 SOLTEAM INCORPORATION CO., LTD.: WINNING IMPERATIVES
  • TABLE 159 YPSOMED AG: PRODUCT BENCHMARKING
  • TABLE 160 YPSOMED AG: KEY DEVELOPMENTS
  • TABLE 161 YPSOMED AG: WINNING IMPERATIVES
  • TABLE 162 ROCHE HOLDING AG: PRODUCT BENCHMARKING
  • TABLE 163 ROCHE HOLDING AG: KEY DEVELOPMENTS
  • TABLE 164 ROCHE HOLDING AG: WINNING IMPERATIVES
  • TABLE 165 NORDIC PHARMA: PRODUCT BENCHMARKING
  • TABLE 166 NORDIC PHARMA: KEY DEVELOPMENTS
  • TABLE 167 NORDIC PHARMA: WINNING IMPERATIVES
  • TABLE 168 PHILLIPS-MEDISIZE CORPORATION: PRODUCT BENCHMARKING
  • TABLE 169 PHILLIPS-MEDISIZE CORPORATION: KEY DEVELOPMENTS
  • TABLE 170 PHILLIPS-MEDISIZE CORPORATION: WINNING IMPERATIVES
  • TABLE 171 MEDTRONIC: PRODUCT BENCHMARKING
  • TABLE 172 MEDTRONIC: KEY DEVELOPMENTS
  • TABLE 173 MEDTRONIC: WINNING IMPERATIVES
  • TABLE 174 DIABETICWAREHOUSE: PRODUCT BENCHMARKING
  • TABLE 175 4ALLFAMILY: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE 1 GLOBAL INJECTION PEN MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 DATA SOURCES
  • FIGURE 6 EXECUTIVE SUMMARY
  • FIGURE 7 GLOBAL INJECTION PEN ESTIMATES AND FORECAST (USD MILLION), 2021-2030
  • FIGURE 8 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • FIGURE 9 GLOBAL INJECTION PEN ABSOLUTE MARKET OPPORTUNITY
  • FIGURE 10 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • FIGURE 11 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT
  • FIGURE 12 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
  • FIGURE 13 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY DOSAGE
  • FIGURE 14 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY END-USERS
  • FIGURE 15 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY PEN ACCESSORIES
  • FIGURE 16 GLOBAL INJECTION PEN MARKET GEOGRAPHICAL ANALYSIS, 2024-30
  • FIGURE 17 GLOBAL INJECTION PEN MARKET, BY PRODUCT (USD MILLION)
  • FIGURE 18 GLOBAL INJECTION PEN MARKET, BY APPLICATION (USD MILLION)
  • FIGURE 19 GLOBAL INJECTION PEN MARKET, BY DOSAGE (USD MILLION)
  • FIGURE 20 GLOBAL INJECTION PEN MARKET, BY END-USERS (USD MILLION)
  • FIGURE 21 GLOBAL INJECTION PEN MARKET, BY PEN ACCESSORIES (USD MILLION)
  • FIGURE 22 GLOBAL INJECTION PEN MARKET, BY GEOGRAPHY (USD MILLION)
  • FIGURE 23 FUTURE MARKET OPPORTUNITIES
  • FIGURE 24 INJECTION PEN MARKET OUTLOOK
  • FIGURE 25 MARKET DRIVERS_IMPACT ANALYSIS
  • FIGURE 26 RESTRAINTS_IMPACT ANALYSIS
  • FIGURE 27 KEY TRENDS
  • FIGURE 28 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 GLOBAL INJECTION PEN MARKET, BY PRODUCT
  • FIGURE 30 GLOBAL INJECTION PEN MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT
  • FIGURE 31 GLOBAL INJECTION PEN MARKET, BY DOSAGE
  • FIGURE 32 GLOBAL INJECTION PEN MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY DOSAGE
  • FIGURE 33 GLOBAL INJECTION PEN MARKET, BY APPLICATION
  • FIGURE 34 GLOBAL INJECTION PEN MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
  • FIGURE 35 GLOBAL INJECTION PEN MARKET, BY END USERS
  • FIGURE 36 GLOBAL INJECTION PEN MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY END USERS
  • FIGURE 37 GLOBAL INJECTION PEN MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
  • FIGURE 38 U.S. MARKET SNAPSHOT
  • FIGURE 39 CANADA MARKET SNAPSHOT
  • FIGURE 40 MEXICO MARKET SNAPSHOT
  • FIGURE 41 GERMANY MARKET SNAPSHOT
  • FIGURE 42 U.K. MARKET SNAPSHOT
  • FIGURE 43 FRANCE MARKET SNAPSHOT
  • FIGURE 44 ITALY MARKET SNAPSHOT
  • FIGURE 45 SPAIN MARKET SNAPSHOT
  • FIGURE 46 REST OF EUROPE MARKET SNAPSHOT
  • FIGURE 47 CHINA MARKET SNAPSHOT
  • FIGURE 48 JAPAN MARKET SNAPSHOT
  • FIGURE 49 INDIA MARKET SNAPSHOT
  • FIGURE 50 REST OF ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 51 BRAZIL MARKET SNAPSHOT
  • FIGURE 52 ARGENTINA MARKET SNAPSHOT
  • FIGURE 53 REST OF LATIN AMERICA MARKET SNAPSHOT
  • FIGURE 54 UAE MARKET SNAPSHOT
  • FIGURE 55 SAUDI ARABIA MARKET SNAPSHOT
  • FIGURE 56 SOUTH AFRICA MARKET SNAPSHOT
  • FIGURE 57 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • FIGURE 58 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 59 ACE MATRIX
  • FIGURE 60 ELI LILLY: COMPANY INSIGHT
  • FIGURE 61 SANOFI SA: COMPANY INSIGHT
  • FIGURE 62 NOVO NORDISK A/S: COMPANY INSIGHT
  • FIGURE 63 MERCK KGAA: COMPANY INSIGHT
  • FIGURE 64 TEVA PHARMACEUTICALS: COMPANY INSIGHT
  • FIGURE 65 0WEN MUMFORD: COMPANY INSIGHT
  • FIGURE 66 HASELMEIER GMBH: COMPANY INSIGHT
  • FIGURE 67 GERRESHEIMER AG: COMPANY INSIGHT
  • FIGURE 68 BIOCON LIMITED: COMPANY INSIGHT
  • FIGURE 69 BD: COMPANY INSIGHT
  • FIGURE 70 ASTRAZENECA: COMPANY INSIGHT
  • FIGURE 71 SHL MEDICAL: COMPANY INSIGHT
  • FIGURE 72 NOVARTIS AG: COMPANY INSIGHT
  • FIGURE 73 SOLTEAM INCORPORATION CO., LTD..: COMPANY INSIGHT
  • FIGURE 74 YPSOMED AG: COMPANY INSIGHT
  • FIGURE 75 ROCHE HOLDING AG: COMPANY INSIGHT
  • FIGURE 76 NORDIC PHARMA: COMPANY INSIGHT
  • FIGURE 77 PHILLIPS-MEDISIZE CORPORATION: COMPANY INSIGHT
  • FIGURE 78 MEDTRONIC: COMPANY INSIGHT
  • FIGURE 79 DIABETES EXPRESS.: COMPANY INSIGHT
  • FIGURE 80 DIABETES EXPRESS: PRODUCT BENCHMARKING
  • FIGURE 81 DIABETICWAREHOUSE: COMPANY INSIGHT
  • FIGURE 82 4ALLFAMILY: COMPANY INSIGHT